ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GH Guardant Health Inc

18.30
0.96 (5.54%)
Apr 24 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,796,232
Bid Price 17.82
Ask Price 18.28
News -
Day High 18.11

Low
15.81

52 Week Range

High
41.06

Day Low 17.34
Company Name Stock Ticker Symbol Market Type
Guardant Health Inc GH NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.96 5.54% 18.30 19:59:58
Open Price Low Price High Price Close Price Prev Close
17.72 17.34 18.11 18.10 17.34
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
21,222 1,796,232 $ 17.83 $ 32,020,981 - 15.81 - 41.06
Last Trade Time Type Quantity Stock Price Currency
19:13:19 1 $ 18.28 USD

Guardant Health (GH) Options Flow Summary

Overall Flow

Bullish

Net Premium

504k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

Guardant Health Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
2.2B 121.71M - 563.95M -479.45M -3.94 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Guardant Health News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No GH Message Board. Create One! See More Posts on GH Message Board See More Message Board Posts

Historical GH Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week16.2318.2715.8116.841,745,4912.0712.75%
1 Month17.8022.5715.8118.682,533,5820.502.81%
3 Months22.2623.3615.8119.412,015,607-3.96-17.79%
6 Months25.8930.3615.8122.201,810,875-7.59-29.32%
1 Year24.4741.0615.8127.211,855,444-6.17-25.21%
3 Years159.92169.42515.8147.461,455,788-141.62-88.56%
5 Years67.64181.0715.8163.111,290,144-49.34-72.95%

Guardant Health Description

Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.

Your Recent History

Delayed Upgrade Clock